Table 2 Clinical characteristics of patients according to the presence or absence of endothelial dysfunction
From: Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction?
Characteristics | Smokers | p | |
|---|---|---|---|
ED + (n = 11) | ED − (n = 18) | ||
Age, years (median, range) | 63 (44–77) | 62 (48–78) | 0.86 |
Male:Female ratio | 7:4 | 16:2 | 0.11 |
Tobacco, pack-years (mean, range) | 54 (30–120) | 46 (10–90) | 0.74 |
Current smokers (n=) | 5 | 10 | 0.96 |
FEV1, % predicted (mean, range) | 79 (67–101) | 92 (66–118) | 0.06 |
OLD (n=) | 0 | 2 | 0.51 |
GOLD 1 (n=) | 0 | 1 | 1 |
GOLD 2 (n=) | 0 | 1 | 1 |
Prior chemotherapy (n=) | 2 | 4 | 1 |
Hypercholesterolemia (n=) | 2 | 1 | 0.53 |
Hypertension (n=) | 2 | 5 | 0.68 |
Diabetes mellitus (n=) | 1 | 3 | 1 |
Treatment by statin (n=) | 1 | 5 | 0.36 |
Vasodilating treatment (n=) | 1 | 3 | 1 |